target audience: TECH BUYER Publication date: Jun 2024 - Document type: IDC Perspective - Doc Document number: # US52303723
Vendors to Watch for Real-World Evidence, Data, Platforms, Technologies, and Consulting Services
Content
List of Figures
Get More
When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.
Related Links
Abstract
This IDC Perspective reviews vendors to watch in the real-world evidence (RWE), data, platforms, technologies, and consulting and provides guidance to technology buyers.
"As the importance of RWD/RWE continues to grow exponentially, the life sciences industry is exploring a rapidly evolving landscape of well-established large players and a boiling cauldron of innovative start-ups. Vendors are also pulling out all the stops to ensure that they innovate and differentiate. Pharmas and biotechs are reevaluating legacy partnerships, looking at long-term strategic alignment, and recognizing that these are not easy decisions. Multiple criteria need to be examined, and the fact that these decisions can have a direct impact on regulatory approvals, costs, and time to market needs to be factored in when architecting a RWD/RWE strategy," said Dr. Nimita Limaye, research VP, Life Sciences R&D Strategy and Technology, IDC.